Amgen Inc. $AMGN Stock Purchased by Krilogy Financial LLC

Key Points

• Krilogy Financial more than doubled its Amgen stake in the third quarter, adding 5,981 shares to hold 11,857 shares worth approximately $5.0 million. Institutional investors collectively own 76.5% of Amgen’s stock.
• Amgen reported quarterly earnings of $6.29 per share on $10.05 billion in revenue, beating analyst expectations, while revenue rose 9.5% year over year. The company’s fiscal 2026 EPS guidance is $22.30–$23.50.
• Amgen pays a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 dividend and a 2.4% yield. Despite mixed analyst views, the stock carries an overall “Hold” rating with an average price target of $387.93.

Krilogy Financial LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 101.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,857 shares of the medical research company's stock after acquiring an additional 5,981 shares during the quarter. Krilogy Financial LLC's holdings in Amgen were worth $4,998,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Affinity Capital Advisors LLC increased its holdings in shares of Amgen by 4.0% during the third quarter. Affinity Capital Advisors LLC now owns 1,003 shares of the medical research company's stock valued at $416,000 after acquiring an additional 39 shares in the last quarter. Mechanics Bank Trust Department lifted its stake in shares of Amgen by 16.4% in the 3rd quarter. Mechanics Bank Trust Department now owns 4,623 shares of the medical research company's stock valued at $1,949,000 after purchasing an additional 653 shares during the period. Spartan Planning & Wealth Management boosted its stake in shares of Amgen by 7.2% during the 3rd quarter. Spartan Planning & Wealth Management now owns 1,047 shares of the medical research company's stock worth $441,000 after acquiring an additional 70 shares in the last quarter. Clay Northam Wealth Management LLC purchased a new position in Amgen during the third quarter worth approximately $209,000. Finally, Forvis Mazars Wealth Advisors LLC increased its holdings in Amgen by 2.7% in the 3rd quarter. Forvis Mazars Wealth Advisors LLC now owns 2,301 shares of the medical research company's stock worth $970,000 after acquiring an additional 61 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Down 1.1%

Shares of NASDAQ:AMGN opened at $412.84 on Wednesday. The firm has a 50 day simple moving average of $414.16 and a 200-day simple moving average of $373.24. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The company has a market capitalization of $223.19 billion, a PE ratio of 18.67, a P/E/G ratio of 3.01 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business's revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts predict that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Insider Buying and Selling

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company's stock, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Weiss Ratings raised Amgen from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday, October 8th. Jefferies Financial Group reiterated a "hold" rating and issued a $410.00 target price on shares of Amgen in a report on Wednesday, September 23rd. Bank of America raised their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a report on Wednesday, August 5th. Piper Sandler boosted their price objective on shares of Amgen from $427.00 to $457.00 and gave the company an "overweight" rating in a report on Thursday, August 20th. Finally, Morgan Stanley dropped their price target on shares of Amgen from $362.00 to $359.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat, Amgen currently has an average rating of "Hold" and an average price target of $387.93.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen's portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.